UNC-2250 is primarily utilized in biomedical research as a potent and selective inhibitor of the MET receptor tyrosine kinase. Its application is significant in studying cancer biology, particularly in understanding the role of MET signaling in tumor growth, metastasis, and resistance to therapies. Researchers employ UNC-2250 to investigate its potential as a therapeutic agent in MET-driven cancers, such as certain types of lung, gastric, and renal cancers. It is also used in preclinical studies to evaluate its efficacy in combination with other targeted therapies or chemotherapeutic agents. Additionally, UNC-2250 serves as a valuable tool in elucidating molecular mechanisms underlying MET pathway activation and its impact on cellular processes.